Effect of rosuvastatin on endothelial and macrovascular function, the complement pathway and cardiovascular risk factors in systemic sclerosis (SSc) patients.
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2015
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- 03 Dec 2015 New trial record